Treating Acute Pancreatitis With Dabigatran, a Pilot Study
Treating Acute Pancreatitis With Dabigatran, a Pilot Study
Researchers are studying the safety and efficacy of Dabigatran in the treatment of acute
 pancreatitis.
Subjects with acute pancreatitis who meet the inclusion and exclusion criteria for the study
 will be recruited. Subjects will be randomized to receive either Dabigatran 150mg daily for
 three days or standard treatment. Vital signs, CBC, inflammatory markers and BMP, and
 bleeding complications will be evaluated daily for the next 7 days of until discharge
 whichever is sooner.
Inclusion Criteria:

 -  Acute Pancreatitis (presence at least two of three features: typical pain, amylase or
 lipase >3 times UNL and AP on images)

 -  18-75 years old

 -  Willingness to sign the informed consent

 -  Symptom onset within 72 hours

 Exclusion Criteria:

 -  Under 18 years of age or over 75 years of age

 -  Pregnancy or lactating

 -  Presence of pseudo aneurysm on CT

 -  Predicted severe acute pancreatitis

 -  Unwilling or unable to sign the informed consent

 -  Had recent surgery or sphincterotomy

 -  Active pathological bleeding

 -  Concurrent use of anti-coagulation

 -  Known serious hypersensitivity reaction to Dabigatran

 -  CrCI <30mL/min or on dialysis

 -  Mechanical prosthetic valves

 -  Liver disease

 -  Cancer

 -  On Chemotherapy or immunosuppressant

 -  Persistent ALT, AST, Akl Phos >2 x ULN

 -  Active hepatitis C, active hepatitis B, and active hepatitis A

 -  Anemia (hemoglobin <10g/dL)

 -  Thrombocytopenia

 -  Concomitant use of P-gp inhibitors